Investment and partnership opportunities
Mapreg SAS, a biotechnology company specialising in the discovery and development of drugs for the treatment of diseases of the central nervous system, is looking for investors or partners in the pharmaceutical industry, to support its development.
The company’s compounds are neurosteroid derivatives that exploit a new mechanism for the protection and repair of nerve fibres. Neurosteroids are steroids which are synthesised in the central nervous system. Their existence was discovered in the laboratory of Etienne Emile Baulieu, president of Mapreg.
The first products are focused on acute and currently untreatable pathologies of the central nervous system, such as spinal cord injury, traumatic brain injury and stroke. The compounds are also relevant to the treatment of age-related neurodegenerative diseases such as Alzheimer's.
Mapreg was founded in 2000 to commercialise Baulieu’s research, and has since raised €2 million. The company is based in the Kremlin-Bicêtre Hospital near Paris.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.